<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588130</url>
  </required_header>
  <id_info>
    <org_study_id>MW2017-06-28</org_study_id>
    <nct_id>NCT03588130</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers</brief_title>
  <official_title>A Multicenter , Prospective, Randomized, Placebo Controlled, Adaptive Design Study Performed to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediWound Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediWound Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, prospective, randomized, placebo controlled, adaptive design&#xD;
      study performed to assess the safety and the efficacy of 5% EscharEx (EX-02) compared to Gel&#xD;
      Vehicle (placebo) and non-surgical standard of care (NSSOC), in debridement of Venous Leg&#xD;
      Ulcers (VLU) (in a ratio of 1:1:1) in debridement of VLU.&#xD;
&#xD;
      The main objective of this study is:&#xD;
&#xD;
      To assess the safety and the efficacy of EscharEx (EX-02 formulation) compared to Gel Vehicle&#xD;
      (placebo) and non-surgical standard of care (NSSOC), in debridement of Venous Leg Ulcers&#xD;
      (VLU).&#xD;
&#xD;
      174 randomized adult patients with VLU that fail to heal for 4 weeks to 2 years, and with&#xD;
      &gt;50% non-viable tissue (necrotic/slough/fibrin) on the VLU. The maximum number of patients to&#xD;
      be enrolled is 225.&#xD;
&#xD;
      The total duration of the study of each participating subject is up to 17 weeks: screening (1&#xD;
      week) + Daily visit period (up to 2 weeks) + Twice-weekly visits period (2 weeks) + Weekly&#xD;
      visits period (10 weeks) + closure confirmation (up to 2 weeks, if applicable).&#xD;
&#xD;
      Each patient will go through 4 periods during the trial:&#xD;
&#xD;
        1. Screening period (2 visits, 7 [+2] days apart). Including: recording demographics,&#xD;
           medical history and concomitant medications, vital signs, physical examination, clinical&#xD;
           laboratory tests, wound photography and assessments and questionnaires (pain, wound&#xD;
           status and QoL). During this period, wounds will be treated by standard treatment (e.g.&#xD;
           appropriate dressing, compression bandage) per investigator discretion, with the&#xD;
           exclusion of mechanical and surgical debridement.&#xD;
&#xD;
           During the one week screening period, patients whose wound size (surface area, as&#xD;
           measured by eKare inSightTM) decreases by more than 20 percent will be excluded.&#xD;
&#xD;
        2. Daily visits period (up to 8 daily site visits within up to 14 days): During the Daily&#xD;
           visit period, the patient will arrive daily to site visits. During each visit, adverse&#xD;
           events, concomitant medication, vital signs and pain will be recorded, the wound will be&#xD;
           washed, photographed and assessed for wound size (by eKare inSightTM), % of non viable&#xD;
           tissue (by clinical assessment), and wound healing status (assessed clinically).&#xD;
&#xD;
           Eligible patients will be randomized into one of the study arms: EX-02, or Gel Vehicle&#xD;
           (Placebo), or NSSOC in a 1:1:1 ratio. Patients will be treated with up to 8 daily 24±3&#xD;
           hours applications or until complete debridement is achieved, whichever occurs first.&#xD;
&#xD;
           On the weekends between treatments of EX-02 or Gel material, the wound will be dressed&#xD;
           with a compatible dressing, and by compression therapy. Patients treated with NSSOC&#xD;
           continue using NSSOC during the weekend according to label or instructions for use, and&#xD;
           compression therapy.&#xD;
&#xD;
        3. Twice-weekly visits period (4 visits within 14 days): the patients will be followed&#xD;
           twice weekly for two weeks, (4 visits within 14 days). During each visit, safety&#xD;
           parameters will be recorded (AEs, concomitant medications, pain, vital signs), the wound&#xD;
           will be washed, photographed and assessed for wound size (by eKare inSightTM), % of&#xD;
           nonviable tissue (by clinical assessment), and wound healing status (assessed&#xD;
           clinically).&#xD;
&#xD;
           The investigator will clinically assess complete debridement, upon achieving a viable&#xD;
           wound bed after removal of all non-viable tissue, suitable for initiation of the wound&#xD;
           healing stage.&#xD;
&#xD;
        4. Weekly visits period (up to10 visits within up to 10 weeks): patients will be followed&#xD;
           once weekly for 10 weeks or until complete wound closure was achieved, (up to10 visits&#xD;
           within up to 10 weeks). During each weekly visit, safety parameters will be recorded&#xD;
           (AEs, concomitant medications, pain, vital signs), the wound will be washed,&#xD;
           photographed and assessed for wound size (by eKare inSightTM), % of nonviable tissue (by&#xD;
           clinical assessment), and wound healing status (assessed clinically).&#xD;
&#xD;
      The investigator will clinically assess complete debridement, upon achieving a viable wound&#xD;
      bed after removal of all non-viable tissue, suitable for initiation of the wound healing&#xD;
      stage.&#xD;
&#xD;
      Complete wound closure defined as skin re-epithelialization without drainage or dressing&#xD;
      requirements confirmed at two consecutive study visits, 2 weeks apart will be assessed&#xD;
      clinically. Thus, if closure occurs close to the end of weekly visit period, i.e. on 9th or&#xD;
      10th visit of the weekly period, an additional confirmation visit will be performed 2 weeks&#xD;
      later.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinding of subjects, study team on sites (e.g. investigators, study nurses etc.) and sponsor team to the assigned treatment will be employed between EX-02 arm and Gel Vehicle arm. Since the NSSOC appearance and dosing regimen are different from that of IMP (EX-02 or Gel vehicle), treatment with NSSOC arm can not be masked to study team or sponsor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of complete debridement in EX-02 vs. Gel Vehicle arms, scored dichotomously (yes/no), clinically assessed</measure>
    <time_frame>up to 8 applications, within 14 days</time_frame>
    <description>The clinical assessor will define complete debridement, after each application during the daily visits period</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>EscharEx (5% EX-02 formulation)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Debridement will be performed with 5% EX-02 for 24±3 hours, up to 8 applications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gel Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Debridement will be performed with Gel vehicle for 24±3 hours, up to 8 applications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-surgical standard of care (NSSOC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Debridement will be performed with NSSOC (Santyl or commercially approved Hydrogel) per routine procedures, until complete debridement is achieved</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EscharEx (5% EX-02 formulation)</intervention_name>
    <description>Active arm</description>
    <arm_group_label>EscharEx (5% EX-02 formulation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gel Vehicle</intervention_name>
    <description>Control arm</description>
    <arm_group_label>Gel Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-surgical standard of care (NSSOC)</intervention_name>
    <description>Santyl (Enzymatic debridement) or commercially approved Hydrogel</description>
    <arm_group_label>Non-surgical standard of care (NSSOC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Patients, men or women, between 18 and 90 years of age,&#xD;
&#xD;
          2. Patients with a VLU (determined by medical history, physical examination, and an&#xD;
             ultrasound scan demonstrating venous insufficiency),&#xD;
&#xD;
          3. Wound is present for at least 4 weeks but no longer than 2 years.&#xD;
&#xD;
          4. The necrotic/slough/fibrin non-viable tissue area is at least 50% of wound area&#xD;
             (assessed by clinical evaluation),&#xD;
&#xD;
          5. Target wound surface area is in the range of 2-100 cm2 (assessed by eKare inSightTM),&#xD;
&#xD;
          6. Patient understands the nature of the procedure, is able to adhere to the protocol&#xD;
             regimen, and provides a written informed consent prior to any study procedure.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Wound size decreased by &gt; 20% after 1 week of standard-of-care-only period (screening&#xD;
             period),&#xD;
&#xD;
          2. Patients with more than one leg ulcer, on the leg of the target wound, with an area&#xD;
             greater than or equal to 2cm2,&#xD;
&#xD;
          3. Signs of clinically significant infection including purulent discharge, deep-tissue&#xD;
             abscess, erysipelas, cellulitis, etc.,&#xD;
&#xD;
          4. Severely damaged skin (e.g. abrasion, exfoliation) extending &gt;2 cm around the wound's&#xD;
             edge,&#xD;
&#xD;
          5. Presence of gangrene, signs of systemic infection, sepsis, or osteomyelitis during&#xD;
             screening phase,&#xD;
&#xD;
          6. Clinical suspicion of skin cancer (e.g. BCC, SCC, melanoma, sarcoma), which was not&#xD;
             ruled out by biopsy,&#xD;
&#xD;
          7. Patients with skin disorders unrelated to the wound that are presented adjacent to the&#xD;
             wound,&#xD;
&#xD;
          8. Patients suffering from chronic skin disorders (Idiopathic Pruritus, Psoriasis,&#xD;
             Panniculitis, Pyoderma Gangrenosum, etc.) that might deteriorate as a result of local&#xD;
             trauma or debridement,&#xD;
&#xD;
          9. Wound has sinus tracts or tunnels extending under healthy tissue (following&#xD;
             debridement &quot;un-roofing&quot;- if relevant), or penetrating into joint capsule,&#xD;
&#xD;
         10. Vascular operations in proximity to the wound in the last month,&#xD;
&#xD;
         11. Patients with primary lymphatic edema,&#xD;
&#xD;
         12. A significant decrease in the arterial blood flow of the extremity&#xD;
&#xD;
         13. Patients with pre-enrolment wounds which are covered by eschar heavily saturated with&#xD;
             iodine or by silver sulfadiazine (SSD) pseudoeschar (i.e. pseudoeschar as a result of&#xD;
             SSD treatment),&#xD;
&#xD;
         14. History of allergy or atopic disease or a known sensitivity to pineapples, papaya,&#xD;
             bromelain or papain, as well as known sensitivity to latex proteins (known as&#xD;
             latex-fruit syndrome), bee venom or olive tree pollen,&#xD;
&#xD;
         15. Patients with poor nutritional status: albumin &lt; 2.5g/dl, poorly controlled Diabetes&#xD;
             Mellitus (for diabetic patients; HbA1c &gt; 12%), anemia (hemoglobin&lt;8 g/dL), a leukocyte&#xD;
             counts &lt; 4,000// μl or &gt;15000/μl, abnormal liver function (AST, ALT&gt;2 x upper limit of&#xD;
             normal range), renal failure (Cr &gt; 2.5 mg/dl), BMI&gt;48,&#xD;
&#xD;
         16. Patients undergoing renal or peritoneal dialysis,&#xD;
&#xD;
         17. Any condition that would preclude safe participation in the study, e.g. evidence of&#xD;
             significant or unstable cardiovascular, pulmonary, liver, hematological,&#xD;
             immunological, or neoplastic disease, or any immediate life threatening condition,&#xD;
&#xD;
         18. Recent history (less than 6 months) of myocardial infarction (MI) or concurrent acute&#xD;
             injury or disease that might compromise the patient's welfare,&#xD;
&#xD;
         19. Patient is currently receiving, or has received at any time within three months prior&#xD;
             to enrollment, any medications or treatments known to affect the wound healing&#xD;
             processes; these include, chronic systemic steroid intake with topical skin changes&#xD;
             (i.e. thin, fragile skin with multiple heamatomas or previous laceration history)&#xD;
             immuno-suppressive drugs, radiation therapy, immunomodulating medications and&#xD;
             chemotherapy,&#xD;
&#xD;
         20. Mentally incapacitated adults who are incapable of giving legal consent (e.g.&#xD;
             dementia, psychiatric patients, etc.),&#xD;
&#xD;
         21. Concurrent use of non-approved drugs or alcohol abuse,&#xD;
&#xD;
         22. Pregnant women (positive pregnancy test) or nursing mothers,&#xD;
&#xD;
         23. Exposure to investigational intervention within three months prior to enrollment, or&#xD;
             anticipated participation in another investigational drug trial or other intervention&#xD;
             trial, while enrolled in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yael Katz-Levy, PhD</last_name>
    <phone>972546774149</phone>
    <email>yaelkl@mediwound.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keren David, MSc</last_name>
    <phone>972542233052</phone>
    <email>kerend@mediwound.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ILD Research Center</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Martinez</last_name>
      <email>eric@ildresearch.com</email>
    </contact>
    <investigator>
      <last_name>Dean Vayser, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limb Preservation Platform, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Destiny Blackstone</last_name>
      <email>Destiny@LPPresearch.com</email>
    </contact>
    <investigator>
      <last_name>Shawn Cazzell, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Felix Sigal. D.P.M, PC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maira Jackson</last_name>
      <email>maira@lafootpain.com</email>
    </contact>
    <investigator>
      <last_name>Felix Sigal, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shannon Meyer</last_name>
      <email>smeyer27@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Gurtner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayana Sarkisova</last_name>
      <email>Gayana@ccr-trials.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Reyzelman, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medstar Health Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariya Beitollahi</last_name>
      <email>ab3535@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Attinger, DPM, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C &amp; R Research Services USA, Inc</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Allongo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INTEGRAL - Clinical Trials Solutions</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linethe Gonzalez</last_name>
      <email>lgonzalez@integralcts.com</email>
    </contact>
    <investigator>
      <last_name>Francisco Perez-Clavijo, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barry University Clinical Research</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Swartz</last_name>
      <email>mSwartz@barry.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Snyder, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aliette Espinosa</last_name>
      <email>aespinosa@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Kirsner, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Liu</last_name>
      <email>jing.liu@nm.org</email>
    </contact>
    <investigator>
      <last_name>Robert Galiano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Levin</last_name>
      <email>JLEVIN7@PARTNERS.ORG</email>
    </contact>
    <investigator>
      <last_name>Jeremy Goverman, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center/Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elga Rodrigues</last_name>
      <email>elga.rodrigues@bmc.org</email>
    </contact>
    <investigator>
      <last_name>Alik Farber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Shore Health System, Center for Wound Healing</name>
      <address>
        <city>Weymouth</city>
        <state>Massachusetts</state>
        <zip>02189</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maureen DeMenna</last_name>
      <email>Mdemmena@southshorehealth.org</email>
    </contact>
    <investigator>
      <last_name>Lisa Gould, MD, PhD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Foot &amp; Ankle Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Claeson</last_name>
      <email>henrik.claeson@afaclv.com</email>
    </contact>
    <investigator>
      <last_name>Cyaandi Dove, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System - Overlook Wound Care Center</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jotsaroop Ahuja</last_name>
      <email>Jotsaroop.Ahuja@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Robert Roland, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bey Lea Ambulatory Surgical Center</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08753</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelley Bongiovanni</last_name>
      <email>kelleybongiovanni@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Matthew Regulski, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Winthrop Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cindy Alsalamarrie</last_name>
      <email>Cindy.Alsamarraie@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Scott Gorenstein, MD FACEP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai St. Luke's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Pesek</last_name>
      <email>emily.pesek@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>John Lantis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Taylor</last_name>
      <email>maria.taylor@stonybrook.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZH Wound Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandon Hoffman</last_name>
      <email>BHoffman@AZHCenters.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Niezgoda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneva</name>
      <address>
        <city>Geneva</city>
        <state>Canton</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence Toutous Trellu, MD</last_name>
      <phone>41-223728993</phone>
      <email>laurence.trellu@hcuge.ch</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Da Silva</last_name>
      <phone>41-225961434</phone>
      <email>td@galser.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Debridement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

